The previous executives of SpringWorks Therapeutics are now back with an even new biotech company that is already buzzing due to a 300 million Series A.
Beeline Medicines launched out of stealth today with its stores already full of an investment team led by Bain Capital, five autoimmune programs licensed by Bristol Myers Squibb to keep its team busy.
Saqib Islam, a former Pfizer spinout SpringWorks leader who oversaw its two FDA approvals and a 3.9 billion acquisition of Merck KGaA in April 2025, is the leader of the Beeline hive.
Islam had initially believed that he and another SpringWorks alum, Badreddin Edris, would have some time off after the sale of their company closed last July. Instead, Bain–builders of SpringWorks–immediately began spinning five BMS programs into a new company, and the prospect was too good to miss.
All this pipeline is based on this crossroads of rigorous science, unmet patient need, and mechanistic rationale. That, plus a group that has some experience of walking the path of execution, makes it very exciting.
The first product of the new biotech is afimetoran, an oral daily small-molecule that inhibits both toll-like receptor 7 (TLR7) and toll-like receptor 8 (TLR8). Afimetoran is already tested on a phase 1b trial in cutaneous lupus erythematosus, with a phase 2 trial already underway and expected to be completed at the end of the year. Subsequently, Beeline will introduce a lupus trial that is pivotal to the prospect, the company announced in an April 15 press release.
TLR7 can be found on innate immune cells and B cells, whereas TLR8 can be found on myeloid cells, as Beeline Chief Medical Officer Nathalie Franchimont, described in the interview with Fierce. The aim of attacking these various immune cells is to prevent lupus, which is characterized by excessive immune response, in its path.
Afimetoran, Franchimont said, is in fact working on the major cause of lupus disease. And since the molecule is meant to be a daily pill, the disease-afflicted people (most of them young women) would find it easy to incorporate the medicine into their lifestyles.
They tend to be young ladies still in college with an active life, she said. I am really excited about having a once-daily, oral, potent therapy that is convenient.
The large population of patients with various types of lupus (around five million) is an opportunity and a liability to the company. It’s this obligation that inspired Beeline’s name, Islam said.
“There’s an accountability that gets created with that, and we have to meet that accountability with a sense of urgency,” the CEO said. Beeline is believed to be the straight line towards a destination. Concentration, commitment, urgency, consistency.
BMS has also seeded the Beeline pipeline with BMS-986326, an IL-2-CD25 fusion protein in phase 1b in atopic dermatitis and lupus, and lomedeucitinib, a phase 2 oral TYK2 inhibitor in plaque psoriasis.
According to the release, the new biotech has two preclinical biologics targeting IL-10 and IL-18.
We have proven biology in both, we have distinguished molecular characteristics in every therapeutic candidate, and then we truly have a good view of clinical milestones within the next year, Edris, now the president and chief operating officer of Beeline, told Fierce.
Beeline anticipates that it will roll out a line of new trials in the next 12-18 months, Edris added, and introduce the two preclinical assets of the biotech to the clinic.
At present, Beeline is concentrating on its five programs with BMS, but the biotech is maintaining a monitor on the overall inflammation and immunology field in case other opportunities blossom, Islam said.
The company currently employs slightly less than 40 staff, mostly R&D heavy, some of which has transferred over to BMS, the chief executive said.
We believe that we will be able to establish a company of consequence in I&I, Islam said. Lupus, but definitely in other indications as well.
A Strategic Launch Backed by Bain
The debut of Beeline Medicines comes with strong financial backing from Bain Capital, which committed $300 million to build a next-generation biotech platform. This funding enables Beeline Medicines to rapidly advance clinical-stage assets rather than starting from early discovery.
The company remained in stealth mode since 2025 before formally launching with a clear focus on precision therapies for immune-mediated diseases.
Five BMS Initiatives Powering the Pipeline
At the core of Beeline Medicines are five therapeutic programs licensed from Bristol Myers Squibb. These initiatives target autoimmune and inflammatory diseases, including lupus, psoriasis, and other immune disorders.
The lead candidate, afimetoran, is already in Phase 2 trials for systemic lupus erythematosus, positioning Beeline Medicines with a relatively advanced clinical pipeline from day one.
In addition to afimetoran, Beeline Medicines is advancing:
- A fusion protein targeting immune regulation
- A TYK2 inhibitor for inflammatory conditions
- Two preclinical biologics addressing novel immune pathways
This diversified portfolio allows Beeline Medicines to compete in the rapidly evolving immunology space.
